📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

Shareholding

About

Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospitals at Noida, Greater Noida, and Noida Extension, Uttar Pradesh.

✓ Strengths 3

Company is expected to give good quarter
Company has delivered good profit growth of 57.4% CAGR over last 5 years
Company's working capital requirements have reduced from 102 days to 80.1 days

! Concerns 1

Company has a low return on equity of 12.1% over last 3 years.

Key Ratios Snapshot

📊 Sector Averages

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔒

Premium Feature

AI-generated 10-section company profile — business model, financials, strengths, risks & management quality

Upgrade to Premium

Already a member? Log in

📐

3-Statement Financial Model

Bear / Base / Bull projections · DCF fair value · Reverse-DCF

Open Model →

Mixed quarter: record revenue (+51.5% YoY to Rs 392.7 Cr) was offset by PAT growth of only +8.0% YoY and a 209 bps YoY drop in reported EBITDA margin to 23.3%, driven by new-hospital ramp-up costs and expense inflation. quarter Investor Presentation One-Pager? Jun 2026

Revenue

Rs 392.7 Cr

+51.5% YoY; +14.9% QoQ

EBITDA Margin

23.3%

down 209 bps YoY; adjusted 28.1% excluding Model Town & Faridabad Sec-20 ramp-up losses

PAT

Rs 45.4 Cr

+8.0% YoY; PAT margin 11.6% vs 16.2% in Q1FY26

Key Metric

ARPOB Rs 34,758

+7% YoY; occupancy 68% vs 71% QoQ

What Went Right

Revenue grew to Rs 392.7 Cr, up 51.5% YoY and 14.9% QoQ, a record quarter.
Adjusted EBITDA margin held at 28.1% excluding Model Town and Faridabad Sec-20 ramp-up losses; new hospitals contributed 27% of revenue vs 22% in Q4FY26.
Faridabad Sec-20 achieved EBITDA breakeven in a record 9 months, with Q1 revenue of Rs 33 Cr (~9% of mix) and latest monthly revenue of ~Rs 12-13 Cr.
Agra hospital posted >20% EBITDA in its first full quarter (Q1 revenue Rs 24 Cr); New Delhi ARPOB reached ~Rs 50K.
Existing hospitals still grew 22% YoY, and the company declared its first interim dividend of 5% of face value.

What to Watch

Reported PAT rose only 8.0% YoY to Rs 45.4 Cr despite 51.5% revenue growth; PAT margin fell 465 bps YoY to 11.6%.
Consolidated EBITDA margin contracted 209 bps YoY to 23.3%, and the 28.1% adjusted margin masks the ongoing drag from Model Town and Faridabad Sec-20.
Employee expenses grew 61.7% YoY and other expenses grew 65.4% YoY, both outpacing revenue growth.
Depreciation jumped 89.3% YoY to Rs 28.2 Cr and finance costs spiked from Rs 0.2 Cr to Rs 6.6 Cr, pressuring PAT.
Occupancy slipped to 68% from 71% QoQ, showing capacity additions are running ahead of utilisation.

Management Guidance

Target ~5,000 bed capacity in next 3 years; announced bed capacity expansion plan of ~3,250 beds.
Gurugram 250-bed under-construction hospital expected operational by Q1 FY28 with proposed outlay of Rs 200 Cr plus additional Rs 100 Cr for medical equipment.
450 brownfield beds proposed at Noida Extension and Greater Noida over next 24 months.

Investor Lens

The top-line beat is real but earnings quality is lagging: revenue +51.5% YoY versus PAT +8.0% YoY, with reported EBITDA margin down 209 bps to 23.3%. The 28.1% adjusted margin excludes the very hospitals causing the dilution, so investors should track consolidated margins until Model Town and Faridabad Sec-20 mature. Faridabad Sec-20's nine-month breakeven and Agra's >20% margin in its first full quarter validate the acquisition playbook, and new hospitals now form 27% of revenue. However, occupancy fell to 68% from 71% QoQ and employee/other costs are compounding faster than revenue. The key catalysts are Model Town's expected H2 FY27 breakeven and a recovery in occupancy; with ~5,000 beds targeted in three years, the company must convert capacity expansion into EPS growth or the current margin compression will persist.

From investor presentation · AI-generated analysis · Not investment advice

🔒

Premium Feature

Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance

Upgrade to Premium

Already a member? Log in

📊 MIXED Revenue up 52% but PAT up just 7% on margin dip to 23%

Revenue

Revenue rose 52.3% YoY to ₹393 Cr, with strong 14.9% QoQ growth. This indicates robust demand momentum in the hospital business.

Profitability

Net Profit grew only 7.1% YoY to ₹45 Cr, flat sequentially. EPS came in at ₹4.88 versus ₹4.36 last year, reflecting weak operating leverage.

Margins

Operating Profit Margin fell to 23% from 25% YoY, a 200 bps contraction. Operating profit grew 43.8% but lagged revenue growth, pointing to higher costs or expansion-related pressures.

Cash Flow

No cash flow data provided.

Balance Sheet

Debt-to-equity is low at 0.15, indicating conservative leverage. No other balance sheet details were provided.

Key Risks

Margin compression despite strong revenue growth is a key concern. High PE of 46.1 leaves limited room for disappointment. PAT growth of just 7% versus revenue growth of 52% highlights weak operating leverage.

Outlook

If revenue momentum continues, operating leverage could restore margins over the coming quarters. However, sustained cost pressures or slower growth may keep profitability subdued.

Generated by AI · Jun 2026 results · Not investment advice

🔒

Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free Account Log In

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to Premium Create Free Account

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to Premium Create Free Account

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Documents.

Access concall transcripts, annual reports, credit ratings, and investor presentations.

Upgrade to Premium Create Free Account

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, SAST trigger, pledge change, concall, and corporate action for this company — in one chronological lane.

Upgrade to Premium Create Free Account

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Forensic Report.

A filings-based disclosure review of this company's most recent Annual Report — Accounting Quality Signals, Related Party Disclosures, Auditor Signals, and Governance Watchpoints, generated with your own AI key.

Upgrade to Premium Create Free Account

📊 Sector KPIs

Industry-specific KPIs with historical trend — AI-extracted from investor presentations

🔒

Premium Feature

Industry-specific KPIs with historical trend across quarters — AI-extracted from investor presentations

Upgrade to Premium

Already a member? Log in

💼 Management Guidance

Revenue, loan book, NIM and other management targets — with hit/miss tracking

🔒

Premium Feature

Management guidance targets with historical hit/miss tracking — unlocked with Premium

Upgrade to Premium

Already a member? Log in

🎯 Thesis Tracker

Guidance vs Delivery — management track record

🔒

Premium Feature

Management guidance vs actual delivery — track whether revenue & PAT targets were Beat, Met or Missed across every reporting year

Upgrade to Premium

Already a member? Log in

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to Premium Create Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.

Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.

Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.

Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.